A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 47/48 (2006.01) A61P 35/00 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2560864
The use of a cancerous disease modifying antibody (CDMAB) 7BD-33-11A, for treating a tumor in humans and methods of isolating and identifying cancerous cells which express a CD63 antygenic moiety. The monoclonal antibody 7BD-33- 11A (ATCC accesssion number PTA-4890), which binds a CD63 antigenic moiety, is cytotoxic to cancer cells which express the antigenic moiety. The monoclonal antibody 7BD-33-11A is useful for delaying the disease progression of a human tumor.
L'invention concerne l'utilisation d'un anticorps modifiant une maladie cancéreuse (CDMAB) 7BD-33-11A pour traiter une tumeur chez les humains ainsi que des procédés permettant d'isoler et d'identifier des cellules cancéreuses qui expriment un fragment de l'antigène CD63. L'anticorps monoclonal 7BD-33-11A (numéro PTA-4890 d'accession à L'ATCC) qui lie un fragment de l'antigène CD63, est cytotoxique pour les cellules cancéreuses qui expriment ledit fragment. L'anticorps monoclonal 7BD-33-11A sert à retarder la progression pathologique d'une tumeur humaine.
Da Cruz Luis A. G.
Findlay Helen P.
Hahn Susan E.
Young David S. F.
Arius Research Inc.
F.hoffmann-La Roche Ag
Gowling Lafleur Henderson Llp
LandOfFree
Cytotoxicity mediation of cells evidencing surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxicity mediation of cells evidencing surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxicity mediation of cells evidencing surface... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1441968